Literature DB >> 32375445

[Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2019 edition)].

.   

Abstract

The formulation of the guidelines for the clinical diagnosis and treatment of lung cancer in line with China's national conditions and multiple discipline cooperation plays an important role in standardizing prevention measures and improving the diagnosis and treatment of lung cancer in China. In order to further improve the diagnosis and treatment of lung cancer in China, improve the outcomes of patients, and provide professional evidence-based medicine advice to clinicians at all levels, the Chinese Medical Association organized specialists in departments of pulmonary medicine, oncology medicine, thoracic surgery, radiotherapy, radiology and pathology throughout the country to perform the work. The recent advances in pathology, genetic testing, immuno-molecule testing, and therapeutic approaches were integrated and the guideline was formulated in combination with international guidelines and China's national conditions. The guideline aims to provide evidence-based, guidance for clinicians at all levels. The guideline covers the screening, diagnosis, pathology, treatment and follow-up of lung cancer.

Entities:  

Keywords:  Diagnosis; Guidelines; Lung neoplasms; Therapy

Mesh:

Year:  2020        PMID: 32375445     DOI: 10.3760/cma.j.cn112152-20200120-00049

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  7 in total

Review 1.  Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review.

Authors:  Zhe Zhang; Sen Yang; Yanfang Ma; Hanqiong Zhou; Xuan Wu; Jing Han; Jiabao Hou; Lidan Hao; Jonathan D Spicer; Young Wha Koh; Mariano Provencio; Noemi Reguart; Tetsuya Mitsudomi; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 2.  The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Ze Peng; Wen Wen Wu; Ping Yi
Journal:  Front Pharmacol       Date:  2021-03-18       Impact factor: 5.810

3.  Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.

Authors:  Tao Hong; Teng Sun; Miao Zhang; Xinlong Liu; Yanliang Yuan; Ponnie Robertlee Dolo; Bi Chen; Hao Zhang
Journal:  Thorac Cancer       Date:  2021-08-30       Impact factor: 3.500

4.  Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.

Authors:  Jiqiang Guo; Ying Gao; Zhihua Gong; Pengfei Dong; Yajie Mao; Fang Li; Jianrong Rong; Junping Zhang; Yongnian Zhou; Huijing Feng; Hongxia Guo; Linxia Gu; Meiwen An; Kaixue Wen; Jin Zhang
Journal:  Biomed Res Int       Date:  2021-10-19       Impact factor: 3.411

5.  Efficacy Analysis of DSA-Guided Bronchial Arterial Chemoembolization Interventional Therapy in Patients with Middle-Advanced Primary Bronchial Lung Cancer.

Authors:  Haili Cao; Shuqiang Jin; Bin Bai
Journal:  Comput Math Methods Med       Date:  2022-03-23       Impact factor: 2.238

6.  Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis.

Authors:  Xinglu Xu; Yuwen Bao; Kai Xu; Zhuolin Zhang; Ningli Zhao; Xin Li
Journal:  Front Public Health       Date:  2022-07-12

7.  Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist.

Authors:  Yongjie Yang; Jingli Lu; Yanfang Ma; Chen Xi; Jian Kang; Qiwen Zhang; Xuedong Jia; Kefeng Liu; Shuzhang Du; Florian Kocher; Andreas Seeber; Cesare Gridelli; Mariano Provencio; Nobuhiko Seki; Yusuke Tomita; Xiaojian Zhang
Journal:  Transl Lung Cancer Res       Date:  2021-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.